Simon Tarsh's most recent trade in Onconetix Inc was a trade of 618 Common Stock done . Disclosure was reported to the exchange on Aug. 15, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Onconetix Inc | Simon Tarsh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2025 | 618 | 658 | - | 0 | Common Stock | |
Onconetix Inc | Simon Tarsh | Director | Other type of transaction at price $ 0.00 per share. | 15 Aug 2025 | 39 | 40 | - | 0 | Common Stock | |
Renovaro Biosciences Inc | Simon Tarsh | Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2024 | 58,500 | 58,500 | - | - | Option to purchase shares of common stock | |
Onconetix Inc | Simon Tarsh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2024 | 3,318 | 3,477 | - | 0 | Common Stock | |
Renovaro Biosciences Inc | Simon Tarsh | Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2024 | 10,000 | 10,000 | - | - | Option to purchase shares of common stock | |
Blue Water Biotech Inc | Simon Tarsh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 6,360 | 6,360 | - | 0 | Common Stock | |
Blue Water Biotech Inc | Simon Tarsh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Aug 2022 | 4,073 | 4,073 | - | - | Stock Option |